These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21187593)

  • 1. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
    Sugimoto T
    Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osteoporosis treatment by anti-RANKL antibody].
    Sugimoto T
    Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P
    Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
    Tankó LB
    Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 16. Denosumab: What's new?
    Bogado CE; Zanchetta MB; Boailchuk JA; Massari FE; Zanchetta JR
    Curr Osteoporos Rep; 2011 Mar; 9(1):12-9. PubMed ID: 21132405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab: anti-RANKL antibody.
    Miller PD
    Curr Osteoporos Rep; 2009 Mar; 7(1):18-22. PubMed ID: 19239825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab: an update.
    Bogado CE; Boailchuk JA; Zanchetta MB; Massari FE; Zanchetta JR
    Drugs Today (Barc); 2011 Aug; 47(8):605-13. PubMed ID: 21850283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T
    Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.